Stock Events

Stock Events

Crossject 

€0.9900
46
+€0.00+0% Wednesday 15:35

Statistics

Day High
1.29
Day Low
0.99
52W High
1.29
52W Low
0.99
Volume
3,831
Avg. Volume
-
Mkt Cap
51.73M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-15.24MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CJBS.PA. It's not an investment recommendation.
TotalEnergies
12
TTE.PA
Lvmh Moet Hennessy Louis Vuitton
10
MC.PA
BNP Paribas
8
BNP.PA
Stellantis N.V
7
STLAP.PA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mannkind
MNKD
Mkt Cap1.31B
MannKind Corporation works on inhaled therapeutic products for diabetes and pulmonary arterial hypertension, offering an alternative to traditional injection methods.
Becton Dickinson
BDX
Mkt Cap50.32B
Becton, Dickinson and Company is a global medical technology company that manufactures drug delivery systems, including injection devices that compete with Crossject's technology.
West Pharmaceutical Services
WST
Mkt Cap23.93B
West Pharmaceutical Services designs and manufactures injectable pharmaceutical packaging and delivery systems, providing competitive products to the drug delivery market.
SeaStar Medical
ICU
Mkt Cap13.13M
ICU Medical, Inc. specializes in the development, manufacture, and sale of innovative medical devices used in infusion therapy and critical care applications, competing with Crossject's drug delivery solutions.

About

Crossject S.A. is dedicated to pioneering needle-free drug delivery solutions. A key innovation from the company is ZENEO, a prefilled, single-use auto-injector that eliminates the need for a traditional needle. Crossject is actively advancing a portfolio of drugs through clinical trials, all intended for administration via its ZENEO system. This pipeline includes Sumatriptan for treating migraines and cluster headaches, Adrenaline for severe allergic reactions (anaphylactic shock), Hydrocortisone for acute adrenal insufficiency, Midazolam for managing epileptic seizures, Naloxone for opioid overdose, Apomorphine for temporary paralysis in Parkinson's patients, Methotrexate for rheumatoid arthritis, and Terbutaline for acute asthma attacks. Founded in 1997, the company maintains its operational base in Dijon, France.
Show more...
CEO
Patrick Alexandre
Employees
99
Country
France
ISIN
FR001400UR90

Listings

PA
FR
CJBS.PA
STU
DE
74C.STU
PA
FR
ALCJ.PA
F
DE
74C.F

0 Comments

Share your thoughts

FAQ

What is Crossject stock price today?▼
The current price of CJBS.PA is €0.99 EUR — it has increased by +0% in the past 24 hours. Watch Crossject stock price performance more closely on the chart.
What is Crossject stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Euronext Paris exchange Crossject stocks are traded under the ticker CJBS.PA.
Is Crossject stock price growing?▼
CJBS.PA stock has risen by +0% compared to the previous week, the month change is a -23.26% fall, over the last year Crossject has showed a +125% increase.
What is Crossject market cap?▼
Today Crossject has the market capitalization of 51.73M
What is Crossject revenue for the last year?▼
Crossject revenue for the last year amounts to 0 EUR.
What is Crossject net income for the last year?▼
CJBS.PA net income for the last year is -15.24M EUR.
How many employees does Crossject have?▼
As of September 10, 2026, the company has 99 employees.
In which sector is Crossject located?▼
Crossject operates in the Health & Wellness sector.
When did Crossject complete a stock split?▼
The last stock split for Crossject was on January 03, 2022 with a ratio of 2:1.
Where is Crossject headquartered?▼
Crossject is headquartered in Dijon, France.